Asensus Surgical — SafeStitch Medical — Investor Presentation (June 2010)
31 slides from Asensus Surgical's investor presentation, Jun 8, 2010
Slide 1: Where Safety Meets Innovation
Where Safety Meets Innovation Endoscopic and Minimally Invasive Surgical Devices www.SafeStitch.com OTCBB: SFES 1 June 2010
Slide 2: Forward-Looking Statements
This presentation contains "forward-looking statements," as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends," "est
Slide 3: Board and Founders
Charles J. Filipi, M.D. Professor of Surgery at Creighton University School of Medicine; Past President of the American Hernia Society; Fellow of the American College of Surgeons Phillip Frost, M.D. Chairman, CEO and President of OPKO Health; Chairman of Teva Pharmaceuticals; Former Chairman and CEO
Slide 4: Management Team
Jeffrey G. Spragens - Chief Executive Officer and President Co-Founder and former Director of North American Vaccine Corporation; Co- Founder and Director of Foundation for Peace; Co-Founder of Mint Management and Development Stewart B. Davis, M.D. - Chief Operating Officer Managing Partner and Medi
Slide 5: Board of Directors
Jane Hsiao Ph.D. - Chairman of the Board Jeffrey G. Spragens Charles J. Filipi, M.D. Chao Chen, Ph.D. Chief Operating Officer of UniMed VM, Former Vice President of TaiMed Inc., Formerly with Cordis and Ethicon, subsidiaries of Johnson & Johnson Richard Pfenniger, Jr. CEO and President of Continucar
Slide 6: Scientific Advisory Board
Para Chondrosoma, M.D. University of Southern California (Chairman of Pathology); Esophageal Pathology Tom DeMeester, M.D. University of Southern California (Chairman of Surgery); Esophageal Surgery; Expert in Barrett's Esophagus Glen Lehman, M.D. Indiana University; Gastroenterology; Expert in Endo
Slide 7: Regulatory and Commercial Milestones
February 2009 - FDA clearance for SMART DilatorTM November 2009 - FDA clearance for AMID StaplerTM February 2010 - CE Mark for AMID StaplerTM June 2010 - Commercial Launch of AMID StaplerTM June 2010 - Commercial Launch of AMID StaplerTM June 2010 - Commercial Launch of AMID StaplerTM June 2010 - Co
Slide 8: Facilities: Miami Headquarters, Labs, Warehouse
Miami Headquarters Development Lab Distribution Warehouse Omaha Office Development Lab Development Lab Development Lab Development Lab Development Lab Development Lab Development Lab Development Lab 8 June 2010
Slide 9: Ready to Launch Sales
Ready to launch sales - June 2010 510(k) cleared by FDA - November 2009 CE Mark received - February 2010 Sales and Marketing Team in place Led by industry veterans, Caron D'Ambruso and J.C. Campbell Campbell Campbell Campbell Campbell Campbell Campbell June 2010 9
Slide 10: AMID Stapler
AMID Stapler™
Slide 11: Hernia Repair Market
Up to 1 million inguinal hernia cases per year in the U.S. Approximately 80% of inguinal hernia repairs worldwide utilize the Lichtenstein method of affixing mesh to the herniated abdominal wall Popularized by UCLA's Parviz Amid, M.D. Hand suturing Significant retraction Approximately 100,000 ventra
Slide 12: AMID Stapler Features
Developed with input from Dr. Amid Can be used to repair Inguinal and Ventral hernias and to staple skin For Lichtenstein repair, The AMID StaplerTM is expected to make the procedure: Fast Easy Reduce post-operative pain Reduce post-operative pain Reduce post-operative pain Reduce post-operative pai
Slide 13: Novel Devices and GI Complementary Products
NOVEL DEVICES and GI Complementary Products Intraluminal Gastroplasty Kit For Obesity For GastroEsophageal Reflux Disorder (GERD) Status - Ready for IDE Intraluminal Fixation Device Status - 510(k) submitted Intraluminal Excision Device Status - 510(k) ready to submit June 2010 Barrett's Excision an
Slide 14: Obesity
Closely linked to heart disease, diabetes, hypertension and other major health issues ~27% of U.S. population may be obese Treated with diet, exercise, prescription drugs and/or surgery Surgery is most effective treatment Current surgical procedures have become household terms (gastric bypass, stoma
Slide 15: Obesity Prevalence in the U.S.
15 June 2010 No Data <10% 10%-14% 15%-19% 20%-24% 25%-29% ^30% (BMI ^30, or ~ 30 lbs. overweight for 5' 4" person) 2008 Source: Behavioral Risk Factor Surveillance System, CDC
Slide 16: Bariatric Surgery Today
350,000 - 400,000 bariatric procedures are currently performed worldwide each year Existing procedures cost $15,000 to $70,000 Existing procedures involve open abdominal surgery High risk patients, with high morbidity and mortality for these procedures mortality for these procedures mortality for th
Slide 17: Intraluminal Gastroplasty Kit for Obesity
Advantages: Outpatient procedure Safer Faster recovery Durability of effect Significant cost reduction Clinical trials expected to begin in Q3 2010 17 June 2010
Slide 18: GastroEsophageal Reflux Disorder
GastroEsophageal Reflux Disorder Heartburn, indigestion Multibillion dollar market in pharmaceuticals alone Recent New England Journal of Medicine papers discuss increased risk of bone fractures with chronic PPI use GERD can lead to Barrett's Esophagus, which may lead to cancer 200,000 to 250,000 GE
Slide 19: Gastroplasty Kit for GERD
Same kit as obesity Advantages: Outpatient procedure Safer Easier and Quicker Durability of effect Significant cost reduction Clinical trials expected to begin in Q3 2010 19 June 2010
Slide 20: Excision Suture Knotter
20 EXCISION SUTURE June 2010 KNOTTER
Slide 21: Intraluminal Fixation and Excision Devices
Intraluminal Fixation Device Status - 510(k) submitted Market - Pouch reduction, Outlet reduction, Gastro-gastro fistula closure, NOTES gastrostomy closure, Esophageal perforation closure, Post colonoscopy rectal sigmoid colon perforation closure, Post endoscopic gastric perforation closure, Gastric
Slide 22: Barrett's Esophagus
Condition in which the esophagus changes so that some of its lining is replaced by a type of tissue similar to that normally found in the intestine, intestinal metaplasia GERD is most common cause May lead to esophageal cancer May lead to esophageal cancer May lead to esophageal cancer May lead to e
Slide 23: Barrett's Excision Device Advantages
Approximately 11 million patients worldwide Advantages: Large piece of tissue excised; can be sent for histology Clean margins Easier and Quicker than EMR and RF Ablation Cost reduction Cost reduction Cost reduction Cost reduction Cost reduction Cost reduction Cost reduction Cost reduction Cost redu
Slide 24: SMART Dilator
SMART Dilator™
Slide 25: SMART Dilator
800,000 dilations of esophageal strictures are performed annually in the U.S.; ~2 million Worldwide Perforation Rate: ~1.1% Important Features Visual feedback force gauge handle Tapered tip Endoscope channel through entire device Disposable: other disposable dilators sell for $150 - $250 Ready to La
Slide 26: Retention Bite Block
Approximately 18 - 20M upper endoscopies done per year worldwide and all procedures need bite blocks to prevent injury to endoscopes and the patients' teeth Class I, 510(k) exempt device Advantages: Harder to expel from mouth Softer material Superior crush resistance Larger working inner diameter La
Slide 27: Airway Bite Block
Approximately 5M upper endoscopies done per year worldwide on obese patients Many obese patients have airway problems during procedures which require intervention Class I, 510(k) exempt device Advantages: Novel design integrating Retention Bite Block and Oral-Pharyngeal airway Softer Material Superi
Slide 28: T Fastener and NOTES Devices
T Fastener For Upper GI Bleeding and closing gastrotomies following NOTES T Fastener can be placed using multi-firing endoscopic device High mortality rate due to Upper GI bleeding Needs to be treated quickly and effectively Novel Devices for NOTES IP for multiple devices: Magnetic retractors Device
Slide 29: Stock Performance - SFES
Stock Performance - SFES Daily $2.13 1.88 1.63 1.38 1.13 1.00 0.88 0.75 0.63 0.50 0.38 18,00 Th 15.00 12.00 9.00 Jun Jul Aug Sep Oct Nov Dec 2010 Feb Mar Apr May 3.00 tote til 9.09 June 2010
Slide 30: Large, Important and Growing Markets
Large, important and growing markets Obesity, GERD, Hernia and Barrett's Esophagus Multibillion dollar markets Unique devices Outpatient and minimally invasive Increased safety for patients Reduce procedural costs Reduce societal costs from obesity and obesity-related diseases obesity-related diseas
Slide 31: Where Safety Meets Innovation - Contact
Where Safety Meets Innovation Contact: Jeffrey Spragens - CEO & President Stewart Davis M.D. - COO Adam Jackson - CFO 4400 Biscayne Boulevard Miami, FL 33137 (305) 575-4600 (305) 575-4130 Fax www.SafeStitch.com OTCBB: SFES 31 June 2010
SafeStitch Medical — Investor Presentation (June 2010) on 6ix